Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019

por Streinu-Cercel, Anca, Săndulescu, Oana, Preotescu, Liliana-Lucia, Kim, Jin Yong, Kim, Yeon-Sook, Cheon, Shinhye, Jang, Young Rock, Lee, Sang Joon, Kim, Sung Hyun, Chang, Ilsung, Suh, Jee Hye, Lee, Seul Gi, Kim, Mi Rim, Chung, Da Rae, Kim, Han Na, Streinu-Cercel, Adrian, Eom, Joong Sik
Publicado 2022

A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019

por Kim, Jin Yong, Săndulescu, Oana, Preotescu, Liliana-Lucia, Rivera-Martínez, Norma E, Dobryanska, Marta, Birlutiu, Victoria, Miftode, Egidia G, Gaibu, Natalia, Caliman-Sturdza, Olga, Florescu, Simin-Aysel, Shi, Hye Jin, Streinu-Cercel, Anca, Streinu-Cercel, Adrian, Lee, Sang Joon, Kim, Sung Hyun, Chang, Ilsung, Bae, Yun Ju, Suh, Jee Hye, Chung, Da Rae, Kim, Sun Jung, Kim, Mi Rim, Lee, Seul Gi, Park, Gahee, Eom, Joong Sik
Publicado 2022